Atea Pharmaceuticals, Inc. (AVIR)


Stock Price Forecast

April 23, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Atea Pharmaceuticals, Inc. chart...

About the Company

We do not have any company description for Atea Pharmaceuticals, Inc. at the moment.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

60

Exchange

Nasdaq

$249M

Total Revenue

60

Employees

$311M

Market Capitalization

-2.32

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AVIR News

Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response

11mon ago, source: Hosted on MSN

E arlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to ...

Atea Pharmaceuticals: Balancing Promising Prospects with Clinical and Regulatory Risks

1mon ago, source: Business Insider

Atea Pharmaceuticals (AVIR) Company Description: Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical ...

Atea Pharmaceuticals Inc Ordinary Shares

13d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

Andrea Corcoran: Yes. Thank you, Jean-Pierre, and thanks, Max, for the question. So, I think as you’ve seen or will see when you have the chance to review the financial statements, we continue ...

Atea Pharmaceuticals, Inc.

1mon ago, source: CNN

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae ...

Atea Pharmaceuticals Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Atea Pharmaceuticals, Inc. Common Stock (AVIR)

6y ago, source: Nasdaq

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Atea Pharmaceuticals, Inc. (AVIR)

1mon ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Atea Pharmaceuticals, Inc. (AVIR)

3d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...